Rhythm Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by Acquired Hypothalamic Obesity Treatments
Rhythm Pharmaceuticals (RYTM) reported third-quarter 2026 global net product revenue of $92.1 million, marking a significant 29% sequential increase from the previous quarter. This growth was primarily fueled by U.S. demand for treatments targeting acquired hypothalamic obesity and Bardet-Biedl syndrome, with U.S. revenue accounting for 73% of total sales. The company reported a GAAP net loss of $41.4 million ($0.61 per share) but maintains a strong liquidity position with $320.9 million in cash and short-term investments, which management expects will fund operations for at least 24 months. Key operational highlights include the expansion of the prescriber base and progress in international markets, specifically identifying over 1,000 potential patients in Japan.
